gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 31 Mar 2015.

Leucine-rich repeat kinase 2

LRRK2, leucine-rich repeat kinase 2, PARK8
This gene is a member of the leucine-rich repeat kinase family and encodes a protein with an ankryin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a MLK-like domain, and a WD40 domain. The protein is present largely in the cytoplasm but also associates with the mitochondrial outer membrane. Mutations in this gene have been associated with Parkinson disease-8. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: AGE, CAN, E3 ubiquitin ligase, PINK1, DJ-1
Papers using LRRK2 antibodies
The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease.
Supplier
Lightowlers Bob, In PLoS ONE, 2009
... For LRRK2, rabbit monoclonal MJFF2 (Epitomics – see ...
LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease
Supplier
Kahle Philipp J., In PLoS ONE, 2009
... ReagentsAll cell culture media and supplements, BacMam LRRK2-GFP reagents, PrestoBlue™ cell viability assay reagent, Western blotting reagents and human neural stem cells were obtained from Life Technologies (Carlsbad, CA) ...
Aggregate formation and toxicity by wild-type and R621C synphilin-1 in the nigrostriatal system of mice using adenoviral vectors
Supplier
Xia Xu-Gang et al., In International Journal of Biological Sciences, 2008
... LRRK2 and tTA transgenic rats were produced by ...
Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein.
Supplier
Feany Mel B., In PLoS ONE, 2007
... Full length WT-LRRK2 pCMV6-XL5 was purchased from Origene (NM_198578.2) ...
Tyramine and octopamine independently inhibit serotonin-stimulated aversive behaviors in Caenorhabditis elegans through two novel amine receptors.
Supplier
Hart Anne C., In PLoS ONE, 2006
... driven WT or mutant LRRK2 constructs, were injected with the co-injection marker, promoter of nmr-1 driven YFP2 [55], into transgenic wild type nematode lines ...
more suppliers
Papers on LRRK2
Lack of exacerbation of neurodegeneration in a double transgenic mouse model of mutant LRRK2 and tau.
New
Beal et al., New York City, United States. In Hum Mol Genet, 24 Apr 2015
UNASSIGNED: LRRK2 (leucine-rich repeat kinase) mutations constitute the most common cause of familial Parkinson's disease (PD).
Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene.
New
LRRK2 AJ consortium et al., Tel Aviv-Yafo, Israel. In Mov Disord, 21 Apr 2015
BACKGROUND: The asymptomatic carriers of the Leucine rich repeat kinase 2 (LRRK2) G2019S mutation represent a population at risk for developing PD.
Low-Variance RNAs Identify Parkinson's Disease Molecular Signature in Blood.
New
Sealfon et al., New York City, United States. In Mov Disord, 18 Apr 2015
The Leucine-rich repeat kinase 2 (LRRK2) G2019S mutation predisposes to PD.
Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease.
Review
New
Wade-Martins et al., Montréal, Canada. In Trends Biochem Sci, 07 Apr 2015
In addition, increasing evidence implicates other PD-associated proteins such as α-synuclein (α-syn) and leucine-rich repeat kinase 2 (LRRK2) in mitochondrial dysfunction in genetic cases of PD with the potential for a large functional overlap with sporadic disease.
Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation.
New
Kassiou et al., Sydney, Australia. In Eur J Med Chem, 03 Apr 2015
UNASSIGNED: LRRK2IN1 is a highly potent inhibitor of leucine-rich repeat kinase 2 (LRRK2, IC50 = 7.9 nM), an established target for treatment of Parkinson's disease.
Chaperone Mediated Autophagy to the Rescue: A New-Fangled Target for the Treatment of Neurodegenerative Diseases.
Review
New
Stefanis et al., Athens, Greece. In Mol Cell Neurosci, 24 Mar 2015
More specifically, it has been suggested that CMA impairment may underlie the accumulation of misfolded / aggregated proteins, such as alpha-synuclein or LRRK2, whose levels or conformations are critical to Parkinson's disease pathogenesis.
The endosomal pathway in Parkinson's disease.
Review
New
Tofaris et al., Oxford, United Kingdom. In Mol Cell Neurosci, 19 Mar 2015
In this review, we summarized the evidence that a number of Parkinson's associated genetic mutations or polymorphisms (LRRK2, VPS35, GBA, ATP13A2, ATP6AP2, DNAJC13/RME-8, RAB7L1, GAK) disrupt protein trafficking and degradation via the endosomal pathway and discussed how such defects could arise from or contribute to the accumulation and misfolding of α-synuclein in Lewy bodies.
Lrrk2 R1628P variant is a risk factor for essential tremor.
New
Tan et al., Singapore, Singapore. In Sci Rep, Dec 2014
PD patients with leucine-rich repeat kinase-2 (LRRK2) mutations may present initially with an ET phenotype.
Inflammation is genetically implicated in Parkinson's disease.
Review
New
Halliday et al., Sydney, Australia. In Neuroscience, Nov 2014
Relatively rare missense mutations in genes such as LRRK2, Parkin, SNCA and PINK1 are causative for familial PD whereas more common variation in genes, including LRRK2, SNCA and GBA, comprise risk factors for sporadic PD.
Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease.
New
Impact
Dawson et al., Baltimore, United States. In Cell, May 2014
Mutations in leucine-rich repeat kinase 2 (LRRK2) are a common cause of familial and sporadic Parkinson's disease (PD).
Multiplying messages LRRK beneath Parkinson disease.
New
Impact
Guo et al., Ann Arbor, United States. In Cell, May 2014
link PD protein leucine-rich repeat kinase 2 (LRRK2) to abnormalities of translational control, a pathogenic mechanism implicated in an increasing number of CNS neurodegenerative diseases, as well as in normal aging.
Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism.
Review
Baekelandt et al., Leuven, Belgium. In Front Genet, 2013
LRRK2 and α-syn have been both linked to familial forms of PD as well as associated to sporadic PD.
Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression.
Impact
Sterneckert et al., Germany. In Cell Stem Cell, 2013
The LRRK2 mutation G2019S is the most common genetic cause of Parkinson's disease (PD).
Progressive degeneration of human neural stem cells caused by pathogenic LRRK2.
Impact
Izpisua Belmonte et al., Beijing, China. In Nature, 2012
We decided to evaluate nuclear organization in the context of ageing-associated disorders by focusing on a leucine-rich repeat kinase 2 (LRRK2) dominant mutation (G2019S; glycine-to-serine substitution at amino acid 2019), which is associated with familial and sporadic Parkinson's disease as well as impairment of adult neurogenesis in mice.
[The absence of the common LRRK2 G2019S mutation in 120 young onset Hungarian Parkinon's disease patients].
GeneRIF
Molnár et al., Budapest, Hungary. In Ideggyogy Sz, 2012
Data suggest that the mutation LRRK2 G2019S may be a rare cause of Parkinson disease in the Hungarian population.
Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations.
GeneRIF
Kortholt et al., Groningen, Netherlands. In Proc Natl Acad Sci U S A, 2012
data give important insight in the LRRK2 activation mechanism and, most importantly, explain the G2019S-related increase in LRRK2 kinase activity
Number and brightness analysis of LRRK2 oligomerization in live cells.
GeneRIF
Jameson et al., Honolulu, United States. In Biophys J, 2012
results show, for the first time to our knowledge, that LRRK2 is predominantly monomeric throughout the cytosol of living cells, but attains predominately higher oligomeric states in the plasma membrane
GST P1, a novel downstream regulator of LRRK2, G2019S-induced neuronal cell death.
GeneRIF
Chen et al., Shanghai, China. In Front Biosci (elite Ed), 2011
results suggest a previously undefined signaling mechanism underlying the neurotoxic effect of LRRK2 (G2019S), in which LRRK2 (G2019S) triggers oxidative stress in cells
Evaluation of the role of LRRK2 gene in Parkinson's disease in an East Indian cohort.
GeneRIF
Ray et al., Calcutta, India. In Dis Markers, 2011
LRRK2 has minimal role as a candidate and susceptibility gene in Parkinson's disease pathogenesis among East Indians.
Pathological roles of α-synuclein in neurological disorders.
Review
Impact
Stefanis et al., Athens, Greece. In Lancet Neurol, 2011
α-Synuclein also seems to be linked to other genetic forms of Parkinson's disease, such as those linked to mutations in GBA or LRRK2, possibly through common effects on autophagy and lysosomal function.
More papers using LRRK2 antibodies
Purification and characterization of Rac 2. A cytosolic GTP-binding protein that regulates human neutrophil NADPH oxidase.
Supplier
Kahle Philipp J., In PLoS ONE, 1991
... The DR4A/3EDD anti-LRRK2-kinase domain antibody is described in reference [35] and goat polyclonal anti 14-3-3 antibody was purchased from Santa Cruz (Santa Cruz Biotechnology, Santa Cruz, CA, USA) ...
share on facebooktweetadd +1mail to friends